Omada Health/$OMDA
Omada Health shares fall as investors focus on management’s forecast for lower Q4 revenue and a slight sequential member decline, despite raised FY26 guidance; Wells Fargo also cut its price target.
10 hours agoLightyear AI
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Omada Health
Omada Health Inc empowers individuals to make lasting health changes through personalized, virtual care between doctor's visits. The integrated platform of the company supports members with cardiometabolic conditions like prediabetes, diabetes, hypertension, musculoskeletal issues, and behavioral health needs. The company's specialized care tracks also assist members using GLP-1 medications. The company delivers measurable health outcomes and value for employers, health plans, health systems, and pharmacy benefit managers.
- Ticker
- $OMDA
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 946
- Headquarters
- South San Francisco, United States
- Website
- www.omadahealth.com
Omada Health Metrics
BasicAdvanced
$1.2B
258.56
$0.07
-
-
Price and volume
Market cap
$1.2B
52-week high
$25.45
52-week low
$10.28
Average daily volume
1.1M
Financial strength
Current ratio
3.907
Quick ratio
3.7
Interest coverage (TTM)
-1.17%
Profitability
EBITDA (TTM)
5.431
Gross margin (TTM)
68.19%
Net profit margin (TTM)
1.39%
Operating margin (TTM)
-0.15%
Revenue per employee (TTM)
$330,000
Management effectiveness
Return on assets (TTM)
-0.09%
Return on equity (TTM)
1.84%
Valuation
Price to earnings (TTM)
258.562
Price to revenue (TTM)
3.593
Price to book
4.54
Price to tangible book (TTM)
4.83
Price to free cash flow (TTM)
64.976
Free cash flow yield (TTM)
1.54%
Free cash flow per share (TTM)
0.292
Growth
Revenue change (TTM)
47.63%
Earnings per share change (TTM)
-102.61%
What the Analysts think about Omada Health
Analyst ratings (Buy, Hold, Sell) for Omada Health stock.
Analyst projections of the future price of Omada Health stock.
Bulls say / Bears say
Third-quarter revenue rose 34% to $91 million and membership grew 36% to 1.1 million. Omada raised its 2026 revenue outlook, signalling that demand is still translating into growth. (Omada Health)
Profitability is improving alongside growth: third-quarter net income was $7 million, gross margin rose to 76% from 66%, and adjusted EBITDA reached $12 million. The company also raised its 2026 adjusted EBITDA outlook to $32–34 million. (Omada Health)
Omada is broadening its routes to market and its care offering. Its HCSC expansion adds access to 1.5 million covered lives, while cholesterol care and a first prescribing customer offer potential routes to future growth. (Omada Health)
Management expects fourth-quarter revenue to fall below the third-quarter level as enrolments ease. Comparisons are also tougher because a partner’s GLP-1 launch drove unusually strong enrolments in the second half of 2025. (Stock Analysis)
Founder and chief executive Sean Duffy is due to become executive chair in January 2027, with President Wei-Li Shao taking over as CEO. The handover adds execution risk while Omada is expanding its products and channels. (Omada Health)
A valuation near four times sales leaves less room for growth to disappoint. Seeking Alpha has also questioned whether Omada’s business has a sufficiently durable competitive moat to support that premium. (Seeking Alpha)
Data summarised monthly by Lightyear AI. Last updated on 6 Nov 2026.
Omada Health Financial Performance
Revenues and expenses
Omada Health Earnings Performance
Company profitability
Upcoming events
No upcoming events
Omada Health News
AllArticlesVideos
Funds containing Omada Health
Fund name | Fund size | $OMDA weighting |
|---|---|---|
SPDR Russell 2000 US Small Cap€R2US | $5.3B | 0.03% |
SPDR Russell 2000 US Small Cap£R2SC | $5.3B | 0.03% |
iShares MSCI World Small Cap$WSML | $9B | 0.01% |
iShares MSCI World Small Cap€IUSN | $9B | 0.01% |
iShares MSCI World Small Cap£WLDS | $9B | 0.01% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.